NCT00515944View on ClinicalTrials.gov

Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

June 30, 2008

Conditions
Healthy
Interventions
DRUG

Botulinum neurotoxin type A, free of complexing proteins

Trial Locations (1)

61273

Merz Pharmaceuticals GmbH, Frankfurt am Main

Sponsors
All Listed Sponsors
lead

Merz Pharmaceuticals GmbH

INDUSTRY